Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
17 results
  • Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Kidney Cancer, Sarcoma, Breast Cancer, Thyroid Cancer, Head and Neck Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Pancreatic Cancer, Esophageal Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Esophageal Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Melanoma, Lung Cancer, Colorectal Cancer, Pancreatic Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations

  • Colorectal Cancer, Lung Cancer, Pancreatic Cancer

23-123          Phase II

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS G12D Mutation

  • Endometrial Cancer, Sarcoma, Esophageal Cancer, Liver Cancer, Gastric (Stomach) Cancer, Bladder Cancer, Pancreatic Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Colorectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer

22-595          Phase II

A Phase 1/2A Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination with BGB-3245 in Patients with Advanced Solid Tumors

  • Melanoma, Gastric (Stomach) Cancer, Pancreatic Cancer, Lung Cancer

24-058          Phase II

A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

  • Breast Cancer, Bladder Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

  • Endometrial Cancer, Gastric (Stomach) Cancer, Kidney Cancer, Lung Cancer, Prostate Cancer, Sarcoma, Colorectal Cancer, Cervical Cancer, Pancreatic Cancer, Breast Cancer, Bladder Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

Showing 1 - 10 of 17 results